CA-VELODYNE/SEOUL-ROBO
27.2.2020 14:02:13 CET | Business Wire | Press release
Velodyne Lidar, Inc. (Booth #6091), in collaboration with Seoul Robotics , will demonstrate how its smart, powerful lidar solutions advance automation and safety in manufacturing and supply chain solutions at MODEX 2020 in Atlanta, March 9-12. Velodyne will highlight lidar sensors that can be used in robotics, automated guided vehicles (AGV), forklifts and security applications. Velodyne lidar solutions can improve industrial automation, materials handling, yard management and distribution center operations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200227005194/en/
At its MODEX booth, Velodyne will showcase the Puck 32MR™, a lidar sensor which produces a data-rich image with the ability to detect low reflectivity objects at a range of 120 meters. The sensor is optimized for outstanding indoor/outdoor performance, operating in a variety of light conditions. By combining high-resolution 3D perception with a broad vertical field of view, the Puck 32MR accurately detects crosswalks, curbs and obstacles in warehouse aisles for safe and efficient navigation in roadway, commercial and industrial settings.
Velodyne will also highlight the Velarray™, a powerful sensor solution to greatly improve automated safety. Its small, embeddable form factor enables the sensor to be seamlessly integrated into a variety of industrial and robotics equipment. The Velarray produces a robust directional image, day or night.
“As the demands for supply chain efficiency and safety increase and evolve, lidar technology is helping companies vastly improve manufacturing and logistics performance,” said Jon Barad, Vice President of Business Development, Velodyne Lidar. “Supply chain systems need to continue to become smarter and safer, more efficient and further automated. To address these requirements, companies are turning to lidar to play a key role in enabling the next generation of manufacturing and supply chain solutions.”
At Velodyne’s MODEX booth, Seoul Robotics will demonstrate the benefits and applications of Level 5 Control Tower solution, powered by its proprietary AI engine, SENSR™, which is optimized and available commercially to process Velodyne’s rich and reliable 3D data. Seoul Robotics uses artificial intelligence (AI) for detection, counting, classification and tracking of objects in real time. It can accurately track the location, coordinates, speed and direction of objects and predict their path, such as vehicles and people at a distribution center or manufacturing and logistics operation.
“As vehicles and material handling equipment are increasingly automated in logistics yards and distribution centers, industry must develop and deploy in parallel a robust and safe operating environment. This will resolve well-known challenges with trucks and equipment, such as blind spots and occlusion, in order to successfully realize the promised efficiency and economy,” said David Han, Seoul Robotics’ Managing Director of North America & Global Automotive. “Level 5 Control Tower equipped with Velodyne lidar enables exactly that – a robust and cost-effective infrastructure-based perception solution that monitors and guides the movement of automated and conventional vehicles within the entire yard – efficiently and safely.”
About Velodyne Lidar
Velodyne provides smart, powerful lidar solutions for autonomy and driver assistance. Headquartered in San Jose, Calif., Velodyne is known worldwide for its portfolio of breakthrough lidar sensor technologies. Velodyne’s founder, David Hall, invented real-time surround view lidar systems in 2005 as part of Velodyne Acoustics. Mr. Hall’s invention revolutionized perception and autonomy for automotive, new mobility, mapping, robotics, and security. Velodyne’s high-performance product line includes a broad range of sensing solutions, including the cost-effective Puck™, the versatile Ultra Puck™, the autonomy-advancing Alpha Prime™, the ADAS-optimized Velarray™, and the groundbreaking software for driver assistance, Vella™.
About Seoul Robotics
Seoul Robotics is a 3D Perception AI company that specializes in Lidar perception solutions, powered by its proprietary and versatile SENSR™ perception platform suite. Based in Seoul, South Korea with U.S. branch office in Ann Arbor, Michigan, Seoul Robotics is developing customers and projects in the ADAS/AV, Security, Smart Factory and Logistics, and Robotics markets worldwide. Seoul Robotics works collaboratively with partners across the value chain – including Lidar manufacturers, global automotive and industrial OEM’s and Tier 1 & 2 suppliers, engineering companies, and government customers – to advance perception solutions that make robots intelligent. Visit www.seoulrobotics.org for more information.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200227005194/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom